MicroVention raises $19 million for MicroPlex launch:
This article was originally published in Clinica
MicroVention, which develops minimally invasive products for the treatment of cerebral vascular diseases, has closed a $19m round of venture capital funding. The Aliso Viejo, California-based company says the new funds will be used to support the second-quarter launch of its MicroPlex coil system and to accelerate sales and marketing of its HydroCoil embolic system for the treatment of cerebral aneurysms. Some 150,000 people are treated for cerebral aneurysms worldwide annually, with 20% undergoing an endovascular coil embolisation procedure, MicroVention says.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.